ALPHAPHARM parent Mylan Inc
has announced a new agreement
with Gilead Sciences under which it
has licensed the rights to produce
and market generic versions of
Gilead HIV/AIDS therapies.
The deal covers single and fixed
dose combinations of products
containing emtricitabine, including
Emtriva and Truvada.
Mylan CEO Heather Bresch said
that “access to affordable
medicines continues to be an acute
need in tackling HIV/AIDS...Mylan is
focused on expanding access to
high quality treatments to those in
need around the world”.
Existing licensing agreements
between Mylan and Gilead cover
other products in late stage clinical
development including integrase
inhibitor Elvitegravir and blood
boosting agent Cobicistat, as well as
finished products such as a generic
version of Viread (tenofovir
disoproxil fumarate or TDF).The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 12
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.